BackgroundGreen tea (Camelliasinensis [L.] Kuntze) belongs to the plant family Theaceae and is mainly distributed in East Asia, the Indian subcontinent and Southeast Asia. This plant has been proven to be beneficial to human health, and green tea is the second most consumed beverage in the world after water. However, until now, the effect of green tea aqueous extract (GTE) upon postmenopausal osteoporosis has remained unclear. In this study, we investigated the therapeutic effects of GTE on estrogen deficiency-induced osteoporosis and explored the possible mechanisms in vivo and in vitro.Materials and methodsOvariectomized (OVX) female rats were orally administered with GTE at doses of 60, 120, and 370 mg kg−1 for 13 consecutive weeks. The biochemical parameters, bone gla protein, alkaline phosphatase, acid phosphatase, estrogen, interleukin-1β, and interleukin-6 in blood samples were detected, and histological change in bones was analyzed by hematoxylin and eosin staining. Meanwhile, the mechanisms of GTE on osteoclast formation were explored in RAW 264.7 cells induced by receptor activation of the nuclear factor kappa B ligand (RANKL).ResultsThe results showed that GTE could increase bone mass and inhibit trabecular bone loss in OVX rats. Furthermore, real-time quantitative reverse transcription polymerase chain reaction analysis from in vitro experiments also showed that GTE reduced the mRNA expression of osteoclast-associated genes such as cathepsin K (cath-K), c-Fos, matrix metalloproteinase 9, nuclear factor of activated T cells cytoplasmic 1 (NFATc1) and tartrate-resistant acid phosphatase. In addition, GTE caused a reduction in the protein levels of NFATc1, c-Fos, c-src and cath-K.ConclusionEvidence from both animal models and in vitro experiments suggested that GTE might effectively ameliorate the symptoms of osteoporosis in OVX rats and inhibit RANKL-induced osteoclast-specific gene and protein expression.
Hyperuricemia is a metabolic disease
caused by impaired uric acid
(UA) metabolism. Ellagic acid (EA) is a natural small-molecule polyphenolic
compound with known antioxidative and anti-inflammatory properties.
Here, we evaluated the regulatory effects of EA on hyperuricemia and
explored the underlying mechanisms. We found that EA is an effective
xanthine oxidase (XOD) inhibitor (IC50 = 165.6 μmol/L)
and superoxide anion scavenger (IC50 = 27.66 μmol/L).
EA (5 and 10 μmol/L) treatment significantly and dose-dependently
reduced UA levels in L-O2 cells; meanwhile, intraperitoneal EA administration
(50 and 100 mg/kg) also significantly reduced serum XOD activity and
UA levels in hyperuricemic mice and markedly improved their liver
and kidney histopathology. EA treatment significantly reduced the
degree of foot edema and inhibited the expression of NLPR3 pathway-related
proteins in foot tissue of monosodium urate (MSU)-treated mice. The
anti-inflammatory effect was also observed in lipopolysaccharide-stimulated
RAW-264.7 cells. Furthermore, EA significantly inhibited the expressions
of XOD and NLRP3 pathway-related proteins (TLR4, p-p65, caspase-1,
TNF-α, and IL-18) in vitro and in vivo. Our results indicated that EA exerts ameliorative effects in experimental
hyperuricemia and foot edema via regulating the NLRP3
signaling pathway and represents a promising therapeutic option for
the management of hyperuricemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.